Racura Oncology (ASX:RAC) Interest Expense: A$0.00 Mil (TTM As of Dec. 2025)


ASX:RAC Racura Oncology Ltd ASX:RAC
31 GF Score
Price A$2.23
View Full Analysis

What is Racura Oncology Interest Expense?

Racura Oncology ASX:RAC +0.90% 31 Interest Expense is A$0.00 Mil as of Dec. 2025. GuruFocus rates ASX:RAC with a GF Score™ of 31/100.

Interest Expense is the amount reported by a company or individual as an expense for borrowed money. Racura Oncology's interest expense for the six months ended in Dec. 2025 was A$ 0.00 Mil. Its interest expense for the trailing twelve months (TTM) ended in Dec. 2025 was A$0.00 Mil.

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income(EBIT) by its Interest Expense. Racura Oncology's Operating Income for the six months ended in Dec. 2025 was A$ -6.01 Mil. Racura Oncology's Interest Expense for the six months ended in Dec. 2025 was A$ 0.00 Mil. Racura Oncology has no long-term debt (1). The higher the ratio, the stronger the company's financial strength is. Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

(1) Note: An indication of "no long-term debt" does not necessarily mean that the company has no long-term debt obligations; it could be due to missing data in the quarterly or annual report. Use caution when interpreting this information.

Racura Oncology  (ASX:RAC) Interest Expense Explanation

Interest Coverage is a ratio that determines how easily a company can pay interest expenses on outstanding debt. It is calculated by dividing a company's Operating Income (EBIT) by its Interest Expense. The higher, the better.

Note: If both Interest Expense and Interest Income are empty, while Net Interest Income is negative, then use Net Interest Income as Interest Expense.

Racura Oncology's Interest Expense for the six months ended in Dec. 2025 was A$0.00 Mil. Its Operating Income for the six months ended in Dec. 2025 was A$-6.01 Mil. And its Long-Term Debt & Capital Lease Obligation for the six months ended in Dec. 2025 was A$0.00 Mil.

Racura Oncology's Interest Coverage for the quarter that ended in Dec. 2025 is calculated as

Racura Oncology had no long-term debt (1).

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

The higher the ratio, the stronger the company's financial strength is.

Good Sign:

Racura Oncology Ltd has no debt.

Racura Oncology Interest Expense Historical Data

* Premium members only.

The historical data trend for Racura Oncology's Interest Expense can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Racura Oncology Interest Expense Chart

Racura Oncology Annual Data
Trend Jun16 Jun17 Jun18 Jun19 Jun20 Jun21 Jun22 Jun23 Jun24 Jun25
Interest Expense
Get a 7-Day Free Trial Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00

Racura Oncology Semi-Annual Data
Jun16 Dec16 Jun17 Dec17 Jun18 Dec18 Jun19 Dec19 Jun20 Dec20 Jun21 Dec21 Jun22 Dec22 Jun23 Dec23 Jun24 Dec24 Jun25 Dec25
Interest Expense Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only 0.00 0.00 0.00 0.00 0.00
ASX:RAC
31GF Score
Racura Oncology Ltd ASX:RAC
Interest Expense is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Racura Oncology Interest Expense Calculation

Interest Expense is the amount reported by a company or individual as an expense for borrowed money.

Interest Expense for the trailing twelve months (TTM) ended in Dec. 2025 adds up the semi-annually data reported by the company within the most recent 12 months, which was A$0.00 Mil.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Frequently Asked Questions Learn more about Interest Expense →
What does a Interest Expense of A$0.00 Mil mean?
Racura Oncology (ASX:RAC) has a Interest Expense of A$0.00 Mil as of Dec. 2025. Interest Expense is the amount a company pays on its long-term debt. View historical data on Racura Oncology and its competitors.
Is Racura Oncology's Interest Expense too high?
Racura Oncology's current Interest Expense is A$0.00 Mil. Overall, Racura Oncology has a GF Score™ of 31/100, reflecting its overall financial health beyond just this single metric.
How does Racura Oncology's Interest Expense compare to VRTX and REGN?
Racura Oncology's Interest Expense of A$0.00 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Interest Expense for a Biotechnology company?
A good Interest Expense depends on the Biotechnology industry context. However, Interest Expense should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Interest Expense mean?
A high Interest Expense can signal that a stock is expensive relative to its fundamentals. Interest Expense is the amount a company pays on its long-term debt. View historical data on Racura Oncology and its competitors. Racura Oncology's current Interest Expense is A$0.00 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Racura Oncology stock overvalued right now?
Racura Oncology (ASX:RAC) has a current Interest Expense of A$0.00 Mil. The current Interest Expense is A$0.00 Mil. Racura Oncology's overall GF Score™ is 31/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Interest Expense calculated?
Interest Expense is calculated from a company's financial statements. For Racura Oncology (ASX:RAC), the current Interest Expense is A$0.00 Mil as of Dec. 2025. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Racura Oncology Business Description

Other Exchanges FN3:Germany
Address 1 Macquarie Place, Level 36, Gateway, Sydney, NSW, AUS, 2000
Racura Oncology Ltd is a developer of an oncology therapeutics platform designed to develop targeted cancer treatments. The company offers precision oncology drug development, biomarker-driven research, and cancer metabolism therapies, enabling healthcare providers and cancer patients to access targeted treatment options with improved therapeutic outcomes.
31GF Score

Get the complete analysis for ASX:RAC

Interest Expense is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

A$2.23
Price